News

Fabhalta® (iptacopan capsules), first oral treatment for adult patients with PNH, now available in Canada
Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...
The American Journal of Managed Care5d
Insights Into Iptacopan in C3 Glomerulopathy: Carla Nester, MD, MSA, FASN
Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...
pharmaphorum5d
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).
pharmaphorum6d
Novartis gets FDA nod for second of three IgAN drugs
It joins the Swiss drugmaker's complement inhibitor Fabhalta (iptacopan) on the US IgAN market, while a third drug developed by the company – subcutaneously administered anti-APRIL antibody ...
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
Spherix Global Insights has released the first edition of its new Patient Dynamixâ„¢: IgA Nephropathy (US) series, delivering a comprehensive look at the IgAN patient journey amid a rapidly evolving ...
Yahoo Finance6d
Emerging IgAN Therapies Bring Hope – But Patients Still Face Emotional and Financial Barriers, According to Spherix Global Insights
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are ...
Zacks Investment Research on MSN10h
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...